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Background: The UK has been severely affected by COVID-19, with speci-
fic challenges in organ transplantation. Here, we describe the co-ordinated
response to, and outcomes from, the ‘first wave’, across all 7 adult and 3
paediatric UK liver transplant (LT) centres.
Methods: Changes to the transplant process were agreed. These included
liver donor age restrictions and changes to offering. A ‘high-urgent’ category
was established (27th Mar–9th Jul), prioritising for LT only those with
UKELD > 60, HCC reaching transplant criteria, and others deemed likely to
die within 90 days. Outcomes were compared with the same time period in
2018 & 2019 when the system of national liver offering by transplant benefit
had been introduced.
Results: There was a significant fall in the number of weekly LT (11 from
18), with an initial drop 84%, before gradual recovery (Figure 1). The retrie-
val rate for deceased donors (71%; P < 0.0001) and, in particular DCD
(35%; P = 0.008) but not DBD (89%; P = 0.2), was higher in 2020, though
subsequent transplant rate was similar.
In total, 188 LT (157 adults and 31 paediatric) were undertaken. Compared
to previous 5 years, paediatric LT was maintained (mean 29); but significant
reduction in adult (37%) and total (32%) LT. Almost all adult LT (148) were
super urgent (n = 15) or high urgent (n = 133). We successfully prioritised
those with highest illness severity (Table 1) with no prolongation of ITU or
hospital stay and no reduction in 90 days patient survival (P = 0.84). There
was a small (5% vs 3%) but significant (P = 0.0012) increase in deaths or
removals from the UK LT waitlist, during this time which occurred predomi-
nantly in the priortised high urgency patients.
Conclusions: During the ‘first wave’ a nationally coordinated response miti-
gated against a significant fall in LT activity. LT recipients with highest need
were prioritised; waitlist mortality was only marginally increased. Transplant
outcomes remained excellent without a significant increase in hospital
resource utilisation.
Figure 1 Number of livers from UK deceased donors offered, retrieved and
transplanted, showing time points in changes to donor age restrictions and
the liver offering scheme (4 Feb -9 Jul 2020)
Table 1 Recipient, donor and transplant characteristics for UK first adult
elective CLD deceased donor liver transplants (27 Mar – 9 July) by year
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Background: The impact of prior SARS-CoV-2 infection on patients on the
waiting list for liver transplantation (LT) and on their post-LT course is pre-
sently unknown.
Methods: Data from adult LT candidates with laboratory confirmed SARS-
CoV-2 infection was collected across Europe and all consecutive patients
with symptomatic COVID-19 were included in the analysis.
Results: From February 21st to November 20th, 2020, 136 adult cases with
laboratory-confirmed SARS-CoV-2 infection from 33 centers in 10 European
countries were collected, with 113 having symptomatic COVID-19. Thirty-
three (29.2%) were managed as outpatients, 80 (70.8%) required hospital-
ization including admission to the intensive care unit (28/80, 35%). Thirty-
seven (37/113, 32.7%) patients died after a median of 18 (10-30) days, res-
piratory failure being the major cause (33/37, 89.2%). The 60-day mortality
risk did not change between first (35.3%, 95% CI 23.9-50.0) and second
wave (26.0%, 95% CI 16.2-40.2). Multivariable Cox regression analysis
showed MELD score !15 (MELD15-19:HR 6.09 95%CI 2.01-18.44;
MELD ! 20:HR 5.21, 95%CI 1.76-15.45) and dyspnea on presentation
(HR:4.1, 95%CI 2.09-8.06) being the two negative independent factors for
mortality. Twenty-six patient received a LT after a median time of 78.5
(IQR:44-102) days and 25 are alive after a median follow-up of 118 days
(IQR:31-170).
Conclusions: Mortality of LT candidates with symptomatic COVID-19 was
high (32.7%) peaking at 45% in decompensated cirrhotic with MELD > 15
and did not significantly differ between the 2 waves of the pandemic, respi-
ratory failure being the major cause of death thus supporting high priority
for vaccination. Prior SARS-CoV-2 infection did not affect early post-trans-
plant survival (96%).
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